转移性去势抵抗性前列腺癌患者PSMA PET/CT的前列腺特异性膜抗原表达:一项回顾性观察研究
本研究为单中心回顾性观察队列研究,纳入160例去势抵抗性前列腺癌(CRPC)患者,比较两次PSMA PET/CT的应答与PSA变化对无进展生存(PFS)和总生存(OS)的预后价值。首次PET/CT时95.0%患者有PSMA表达;PET/CT应答与PSA应答一致率79%(k=0.553);PET/CT应答是不依赖PSA变化的PFS显著预后因素,但OS在应答者与非应答者间无显著差异。
要点
- 首次PSMA PET/CT时152例(95.0%)CRPC患者有PSMA表达,与既往系统治疗无关。
- PET/CT与PSA应答一致率79%(k=0.553,P<0.001);PET/CT应答是不依赖PSA变化的PFS显著预后因素。
- PET/CT应答者与非应答者OS无显著差异;作者认为PSMA PET/CT可能是有用的疗效预测影像方法。
核心结论
- PSMA PET/CT可能是预测mCRPC患者治疗应答的有用影像方法,无论正在进行的系统治疗为何。
- 数据还提示,PET/CT评估的应答对PFS而言可能是比PSA更有意义的预后因素。
- 需要进一步研究以理解PSMA表达在生存中的潜在作用。
研究设计与样本
- 单中心、回顾性观察队列研究,患者来自PSMA-PROSTATA注册研究(EudraCT:2015-004589-27)。
- 共160例CRPC患者纳入分析,其中63例纳入PFS/OS分析。
- 进行首次和第二次(如适用)PSMA PET/CT以确定PSMA表达(无或有),并比较两次PET/CT评估应答。
主要发现
- 首次PET/CT时152例(95.0%)患者有PSMA表达(归类为mCRPC),与既往系统治疗无关。
- SUVmax与基线PSA水平及PSA速度均呈正相关(均P<0.001)。
- 按PET/CT应答,非应答者首次PET/CT的中位SUVmax数值上低于应答者(17.5 vs 20.4;P=0.127)。
- PSA升高者首次PET/CT中位SUVmax(15.8)显著低于PSA下降者(30.4;P=0.018)。
- 纳入PFS/OS分析的63例中,76.2%复发、36.5%在24个月随访前死亡;中位PFS和OS分别为6.1个月和24个月。
关键数值与推荐
- PET/CT应答定义为稳定疾病、部分缓解或完全缓解,非应答定义为疾病进展,通过比较首次与第二次PET/CT判定。
- PFS定义为第二次PET/CT至PSA复发或影像学进展证据的时间。
- 非应答者首次与第二次PET/CT间PSA平均变化146%,应答者为-57%(P<0.001)。
- PET/CT与PSA应答一致率为79%(k=0.553,P<0.001)。
- PET/CT应答是不依赖PSA变化的PFS显著预后因素;OS在PET/CT应答者与非应答者间无显著差异。
临床怎么用
- 原文结论未据此给出推荐,仅指出PSMA PET/CT可能是预测mCRPC治疗应答的有用影像方法。
- 原文指出数据提示PET/CT评估的应答对PFS可能是比PSA更有意义的预后因素。
- 原文指出需要进一步研究以理解PSMA表达在生存中的潜在作用。
局限性
- 原文指出需要进一步研究以理解PSMA表达在生存中的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monitoring therapy response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with novel hormonal therapies, taxanes, and newly approved therapies is crucial for optimizing treatment. [68Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PSMA PET/CT) is a promising target for managing treatment in patients with prostate cancer. PSMA is overexpressed in patients with mCRPC; understanding how expression might change in patients undergoing treatment could determine its potential for guiding clinical decisions. We examined PSMA expression in patients with CRPC and compared PET/CT response with prostate-specific antigen (PSA) variation as a prognostic factor for progression-free survival and overall survival (PFS and OS, respectively). Methods: This was a single-center, retrospective observational cohort study in patients with CRPC enrolled in the PSMA-PROSTATA registry study (EudraCT: 2015-004589-27). A first and second (if applicable) PSMA PET/CT were performed to determine PSMA expression (absence or presence). PET/CT response was assessed as responders (patients with stable disease, partial or complete response) versus nonresponders (patients with progressive disease) by comparing the first with the second PET/CT. PSA variation (increase or decrease from baseline) was assessed across the same time period. PFS was defined as the time between second PET/CT and PSA recurrence or evidence of radiologic progression. Results: Overall, 160 patients with CRPC were included in the analysis. At first PET/CT, nearly all (n = 152; 95.0%) patients had PSMA expression (classified as mCRPC), irrespective of prior systemic therapy. SUVmax was positively associated with baseline PSA levels and velocity (both P < 0.001). According to PET/CT response, median SUVmax on first PET/CT was numerically lower in nonresponders than in responders (17.5 vs. 20.4; P = 0.127). Similarly, patients with a PSA increase had significantly lower median SUVmax on first PET/CT (15.8) than did those with a PSA decrease (30.4; P = 0.018). PSA change was, on average, 146% in nonresponders and -57% in responders between first and second PET/CT (P < 0.001). Agreement between PET/CT and PSA response was 79% (k = 0.553, P < 0.001). Among the 63 patients included in PFS/OS analyses, 76.2% had a relapse and 36.5% died before 24-mo follow-up; median PFS and OS were 6.1 and 24 mo, respectively. PET/CT response, independent of PSA variation, was a significant prognostic factor for PFS. OS was not significantly different between PET/CT responders and nonresponders. Conclusion: PSMA PET/CT may be a useful imaging method predictive of treatment response in patients with mCRPC, regardless of ongoing systemic therapy. Data also suggest that response assessed by PET/CT is a potentially more significant prognostic factor than PSA for PFS. Further studies are needed to understand the potential involvement of PSMA expression on survival.
引用
- Calderoni L, Maietti E, Farolfi A, et al. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study. J Nucl Med. 2023. PMID: 36635087. doi:10.2967/jnumed.122.264964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。